McKesson Corporation (MCK)

Rating: HOLD

HOLD (5-tier) · quality defensive · conviction: medium

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -3% vs spot
• Monte Carlo median implies -19% vs spot
• DCF fair value implies +0% vs spot — but this is terminal-value sensitive (exit-multiple $810 vs Gordon $1,012, 25% apart), so it carries less weight
• Bear case (Structural — Channel Disintermediation / Reimbursement) downside is -55% vs spot
• Net: reward/risk of 0.1× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Investment Thesis

At about $756 the market values McKesson near 17 times forward earnings, a mid-teens multiple that treats the distributor as a low-growth, low-margin toll on drug volumes rather than a specialty franchise. Spot is essentially level with our probability-weighted target of roughly $753, so the tape already prices steady, unremarkable compounding. Our engine agrees the earnings stream is thin-margin and volume-driven: the base case pairs ~5% revenue growth with a ~1.6% operating margin and a 17.5 multiple, anchoring EPS near $48. Peers frame the range, with the EV/revenue median implying roughly $784 and the forward-P/E median near $693. The rating is HOLD because the probability-weighted target and the DCF anchor of about $782 both bracket spot, leaving no margin of safety on either side. The single most damaging risk is structural: if payers and manufacturers extract margin from the distribution channel, both the ~1.6% margin and the mid-teens multiple compress together, and the bear target of roughly $383 sits below the 52-week low of $634.

The dashboard below is the whole argument on one page: spot ($807) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The most probable bear mechanism is not a crash but slow channel disintermediation. McKesson earns roughly 1.6 cents of operating margin per revenue dollar, so it has almost no cushion. If manufacturers widen direct-to-payer and direct-to-pharmacy arrangements, and generic deflation outruns specialty mix gains, the segment margin drifts toward the low-1% range on flat-to-declining volumes. Thin economics leave earnings highly sensitive: a fractional margin loss removes a large share of profit. The market would then re-rate the stream from a mid-teens toll multiple toward a structurally-impaired one, and earnings and multiple compress in the same direction. That combination, not a single bad quarter, is what carries the target below the 52-week low.

Key Debate

Gross Margin explains 82% of Monte Carlo outcome variance — the single variable that decides which side is right.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.56 vs analyst floor +0.38 → delta +0.18 (n=21 mgmt / 13 Q&A; 10th pctile across the S&P book, z -1.3).

Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).

News (last 365d, 1000 articles): avg ticker sentiment +0.23 (bullish 30% / bearish 2%)

Scenario Analysis

The tree runs from a structural 'Structural — Channel Disintermediation / Reimbursement' downside ($367) to a 'Bull — Re-Rate' bull case ($1,197); the probability-weighted blend (PWEV $781) is -3% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Channel Disintermediation / Reimbursement (20%, $367). Structural impairment — channel disintermediation / reimbursement: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 382.88; probability: 0.2.
• Volume / Generic-Deflation Pressure (17%, $680). Cyclical downturn — pharmaceutical distribution volumes + specialty/biosimilar mix + generic deflation weakens for 1–2 years before normalising. Drivers — implied_target: 619.3; probability: 0.17.
• Base — Drug-Volume + Specialty Growth (35%, $834). Mid-cycle — normalised pharmaceutical distribution volumes + specialty/biosimilar mix + generic deflation; disciplined capital allocation; steady returns. Drivers — implied_target: 791.94; probability: 0.35.
• Growth — Specialty / Services Expansion (20%, $1,023). Upside — specialty + services expansion lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 999.91; probability: 0.2.
• Bull — Re-Rate (8%, $1,197). Upside tail — sustained tight conditions or a structural re-rate on specialty + services expansion. Drivers — implied_target: 1176.03; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $654 and 37% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (82% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.0%, 14x terminal FCF multiple → $810. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 15.65x) implies $693. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is 20% of the median — moderate (healthy method disagreement — read the blend with care).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Services

This name sits in the Health Services as a distributors. pharmaceutical distribution volumes + specialty/biosimilar mix + generic deflation Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: MCK (distributors) · COR (distributors) · CAH (distributors) · DGX (diagnostics) · LH (diagnostics) · HSIC (distributors)

Mapping note: name-level 'Structural — Channel Disintermediation / Reimbursement' (20%) + 'Volume / Generic-Deflation Pressure' (17%) map to cluster Reimbursement / Disintermediation Pressure (37%); name-level 'Growth — Specialty / Services Expansion' (20%) + 'Bull — Re-Rate' (8%) map to cluster Upside — Specialty / M&A Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Reimbursement / Disintermediation Pressure () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The health_services cycle is the shared macro driver. Driver — drug/lab volumes + reimbursement + thin-margin distribution & specialty mix Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 1% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.0% · Σ PV(FCF) $28B + PV(terminal) $72B = EV $100B; + net cash → equity $96B ÷ diluted shares 0.12B = $810/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $1,012/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 44% vs WACC 8% → above WACC — the build is value-creative.

Peer set

Peer-median fwd P/E → $693; EV/Rev → $778.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Drug Distribution multiple (AI re-rating) (base 17x)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2026-03-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: cash conversion (OCF/NI) 129% — cash-backed.

Catalyst Calendar

• 2026-05-07 (~-62d) — Fiscal-year results + FY2027 adjusted-EPS guidance and buyback authorization (authored)
• 2026-08-05 (~28d) — Quarterly earnings — est. EPS $9.63 (AV EARNINGS_CALENDAR)
• 2026-10-15 (~99d) — GLP-1 distribution-volume / margin update as branded-drug mix shifts (authored)
• 2027-02-04 (~211d) — Specialty / oncology-platform M&A or partnership milestone (Core Ventures / provider-services build-out) (authored)

Forecast Track Record

• EPS surprise: beat 100.0% of the last 8 quarters; average surprise +3.7%.

Competitive Moat

Wide moat. McKesson's wide moat is scale-and-logistics: a three-firm distribution oligopoly (with ABC/CAH) whose density, cost-per-package and manufacturer relationships are near-impossible to replicate, supporting a terminal multiple around 15-17x despite thin ~1-2% operating margins; the falsifiable test is operating-margin stability and specialty/oncology mix growth — if Amazon/Cost Plus or PBM-integrated distribution takes share and unit economics slip, the moat is narrowing and the multiple should compress toward the market ~13-14x.

Moat sources:

• FACT: US pharma distribution is a ~90%-share oligopoly (MCK/ABC/CAH); scale density drives the lowest cost-per-package
• FACT: specialty/oncology (US Oncology Network, provider services) is a higher-margin, stickier adjacency built on physician relationships
• INFERENCE: manufacturer contracts and DEA-controlled logistics create high barriers to new entrants
• ABSENCE: core distribution is a low-margin, price-taking business — the moat is cost-scale, not pricing power over payers

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 16.0× forward EPS, vs the house DCF terminal 14.0×, and a peer median 15.65×. The house DCF sits 0% above spot, so the market is pricing in less than the house case.

Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 16.6× (simple median 15.65×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $634–$998, centre $796 (-1% vs spot); spot sits at the 48th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Re-Rate): $1,197.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (2566.0); Revenue CAGR ±3pp (218.0); Terminal × ±15% (183.0); WACC ±1pp (70.0); Capex intensity ±15% (18.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 14×, FY+5 revenue $496B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• US Pharmaceutical segment operating margin < 0.0135 (2 consecutive prints → Reimbursement / Disintermediation Pressure). The base thesis rests on a ~1.6% blended operating margin holding despite generic deflation. A sustained slide toward the structural/bear midpoint would signal that payers and manufacturers are extracting channel margin rather than a transient mix effect.
• Adjusted operating profit growth, US Pharmaceutical segment < 0.03 (2 consecutive prints → Mid-Cycle — Volume + Specialty Growth). Base and volume-pressure scenarios diverge on whether segment profit compounds mid-single-digits. Two prints below the base/bear midpoint would move probability weight toward the cyclical-pressure state.
• Consolidated revenue growth < 0.03 (2 consecutive prints → Reimbursement / Disintermediation Pressure). The base case assumes ~5% revenue growth; the volume/deflation scenario runs at 3%. Two prints beneath that midpoint would indicate volumes are decelerating rather than specialty mix carrying the top line.
• Fiscal-year adjusted EPS guidance revision < 0.0 (single event → Reimbursement / Disintermediation Pressure). A downward cut to the full-year adjusted EPS range would directly contradict the earnings compounding embedded in the base target and would validate the earnings leg of the disintermediation scenario.
• Trailing-twelve-month operating cash flow < 5.0 (2 consecutive prints → Mid-Cycle — Volume + Specialty Growth). The distributor model depends on negative working capital and steady cash conversion to fund buybacks. TTM operating cash flow falling below roughly $5B would question the return-of-capital assumption underpinning the diluted-share divisor.

Fact / Inference / Speculation

• FACT: Spot $807; 52-week range $634–$998; engine rating HOLD; base-case target $753 (-7%). (source: Alpha Vantage 2026-06-27, 8 July 2026)
• INFERENCE: Triangulated FV $760 (-6% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits above the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Recommendation: HOLD

Balanced: triangulated fair value $760 (-6% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin — a fundamental call.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.